ATHENS, Greece--(BUSINESS WIRE)--May 13, 2005--Currently, molecular diagnostics
market needs fast, personalized diagnosis, easy to handle methods, decreased
cost and fast therapy decision without compromise in accuracy and reliability.
Once these needs are covered a clear increase in growth rate of molecular diagnostics
is expected. PCR applications in particular will reveal double-digit growth
having the biggest share since PCR remains the workhorse for molecular genetic
analysis.
Acrongenomics
Inc. (OTCBB:AGNM) is currently conducting a clinical
comparison study of its Nano-JETA(TM) Real Time
PCR against the "gold standard", the common
Real Time PCR technology, via the detection of Ep-CAM,
HER1, HER2, vEGF and beta-actin genes in peripheral
blood samples of 500 patients suffering from breast,
colon, lung and ovarian cancer.
The
objective of the study is to evaluate and compare
the Nano-JETA(TM) Real Time PCR technology against
the "gold standard" Real
Time PCR protocols in regards to stability, sensitivity,
specificity, reproducibility and compatibility
by using three different types of Real Time PCR
equipment to perform the Nano-JETA(TM) Real Time
PCR application:
a) iCycler(TM) Real-Time PCR
b) Chromo4(TM) Real-Time PCR
c) Light cycler(TM) Real Time PCR
The study has been designed intentionally to incorporate
the most difficult parameters such as blind control,
multi-centre with variant and unidentified patient
status (primary or metastatic status, follow up or
on treatment).
Acrongenomics Inc. is a Research and Development
company focusing in the field of Nanobiotechnology
and has reshaped key IVD molecular applications such
as PCR, ELISA and Real Time PCR through its Nano-JETA(TM)
technology platform, by integrating nanotechnology
into molecular biology. Acrongenomics Inc.
Tom Skarpelos, 800-689-8181 (Investor Relations)
info@acrongen.com
Lambros Pentafronimos
Investor Relations
Acrongenomics Inc.
Poseidonos 38A
Alimos, 17455
Athens, Greece
+30-210-9859203
|
